Literature DB >> 9736226

Directions for research in autoimmune thrombocytopenic purpura (ITP).

J Freedman1, M B Garvey, G Elinder, V S Blanchette.   

Abstract

All attendees participated in a round-table discussion regarding directions for research in autoimmune thrombocytopenic purpura (ITP). Suggested areas for study were grouped into five main areas: (i) improved classification of ITP identifying subsets of patients with differing clinical syndromes and response to treatment, and those more likely to have serious bleeding manifestations; identification of patients with reduced thrombopoiesis was emphasized; (ii) studies aimed at elucidating the aetiology and pathophysiology of ITP, with emphasis on distinctions between acute and chronic ITP and between patients responsive or refractory to therapy; these studies focused on measures of humoral and cellular immune dysregulation; (iii) studies of platelet function in ITP, with the intent of defining these abnormalities and correlating them with the clinical manifestations of the disease; (iv) new approaches to treatment, particularly of refractory patients; and (v) a miscellaneous group, which included development of an ITP registry, evaluation of the "burden" of disease, investigation of mood changes in ITP, etc. The discussion was not intended to be all-inclusive, but focused on the content of other talks in this symposium. It is hoped that some of these suggestions will be further developed for investigation in multicentre co-operative studies to improve the diagnosis, understanding and treatment of ITP.

Entities:  

Mesh:

Year:  1998        PMID: 9736226     DOI: 10.1111/j.1651-2227.1998.tb01241.x

Source DB:  PubMed          Journal:  Acta Paediatr Suppl        ISSN: 0803-5326


  1 in total

1.  Comparative of three methods (ELIZA, MAIPA and flow cytometry) to determine anti-platelet antibody in children with ITP.

Authors:  Mohsen Hamidpour; Ghader Khalili; Nader Tajic; Bi Bi Shahin Shamsian; Rafie Hamidpour
Journal:  Am J Blood Res       Date:  2014-12-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.